Surrogate markers of treatment outcome in major depressive disorder

International Journal of Neuropsychopharmacology

Volumn 15, Issue 6, 2012, Pages 841-854

  Papakostas, George I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Marker; mediator; moderator; predictor; surrogate

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LIOTHYRONINE; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; REBOXETINE; SERTRALINE; VENLAFAXINE;

AGE; ANXIETY DISORDER; BRAIN FUNCTION; CARDIOVASCULAR RISK; DICHOTIC LISTENING; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; ELECTROENCEPHALOGRAPHY; EVOKED AUDITORY RESPONSE; FOLIC ACID DEFICIENCY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENDER; GENE DELETION; GENE INSERTION; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOLOGY; MAJOR DEPRESSION; METABOLISM; MOLECULAR BIOLOGY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RACE; REMISSION; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMANS;

EID: 84862143442     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001246     Document Type: Review

References (154)

1. Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, et al. (2005). Executive dysfunction and the course of geriatric depression. Biological Psychiatry 58, 204-210. (Pubitemid 41112268)
2. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, Latoussakis V, et al. (2008). Microstructural white matter abnormalities and remission of geriatric depression. American Journal of Psychiatry 165, 238-244. (Pubitemid 351704524)
3. Angst J, Scheidegger P, Stabl M (1993). Efficacy of moclobemide in different patient groups: results of new subscales of the Hamilton Depression Rating Scale. Clinical Neuropharmacology 16 (Suppl. 2), S55-S62. (Pubitemid 23341466)
4. Arias B, Catalan R, Gasto C, Gutierrez B, et al. (2003). 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-week follow up study. Journal of Clinical Psychopharmacology 23, 563-567. (Pubitemid 37443187)
5. Arolt V, Peters M, Erfurth A, Wiesmann M, et al. (2003). S100B and response to treatment in major depression: a pilot study. European Neuropsychopharmacology 13, 235-239. (Pubitemid 36904049)
6. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B (2009). How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology 24, 269-275.
7. Bares M, Brunovsky M, Kopecek M, Stopkova P, et al. (2007). Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. Journal of Psychiatry Research 41, 319-325. (Pubitemid 44854994)
8. Bondy B, Baghai TC, Zill P, Schule C, et al. (2005). Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. Progress in Neuropsychopharmacology and Biological Psychiatry 29, 1094-1099. (Pubitemid 41080136)
9. Bozina N, Peles AM, Sagud M, Bilusic H, et al. (2008). Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World Journal of Biological Psychiatry 9, 190-197.
10. Bruder GE, Otto MW, McGrath PJ, Stewart JW, et al. (1996). Dichotic listening before and after fluoxetine treatment for major depression: relations of laterality to therapeutic response. Neuropsychopharmacology 15, 171-179. (Pubitemid 26255164)
11. Bruder GE, Stewart JW, McGrath PJ, Deliyannides D, et al. (2004). Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men. Neuropsychopharmacology 29, 1752-1761. (Pubitemid 39150116)
12. Bruder GE, Stewart JW, Schaller JD, McGrath PJ (2007). Predicting therapeutic response to secondary treatment with bupropion: dichotic listening tests of functional brain asymmetry. Psychiatry Research 153, 137-143. (Pubitemid 47539596)
13. Bruder GE, Stewart JW, Voglmaier MM, Harrison WM, et al. (1990). Cerebral laterality and depression: relations of perceptual asymmetry to outcome of treatment with tricyclic antidepressants. Neuropsychopharmacology 3, 1-10. (Pubitemid 20077390)
14. Burns RA, Lock T, Edwards DR, Katona CL, et al. (1995). Predictors of response to amine-specific antidepressants. Journal of Affective Disorders 35, 97-106.
15. Caligiuri MP, Gentili V, Eberson S, Kelsoe J, et al. (2003). A quantitative neuromotor predictor of antidepressant non-response in patients with major depression. Journal of Affective Disorders 7, 135-141. (Pubitemid 37363341)
16. Chen CH, Ridler K, Suckling J, Williams S, et al. (2007). Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biological Psychiatry 62, 407-414. (Pubitemid 47284016)
17. Choi MJ, Kang RH, Ham BJ, Jeong HY, et al. (2005). Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 52, 155-162.
18. Choi TK, Koo MS, Lee SH, Seok JH, et al. (2007). Serotonin transporter gene polymorphism associated with venlafaxine treatment response. European Neuropsychopharmacology 17 (Suppl. 4), S228.
19. Cook IA, Leuchter AF, Morgan M, Witte E, et al. (2002). Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 27, 120-131. (Pubitemid 34626748)
20. Cook IA, Leuchter AF, Morgan ML, Stubbeman W, et al. (2005). Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. Journal of Psychiatry Research 39, 461-466. (Pubitemid 40909989)
21. Davidson JR, Meoni P, Haudiquet V, Cantillon M, et al. (2002). Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depression and Anxiety 16, 4-13. (Pubitemid 34977120)
22. Davidson RJ, Irwin W, Anderle MJ, Kalin NH (2003). The neural substrates of affective processing in depressed patients treated with venlafaxine. American Journal of Psychiatry 160, 64-75. (Pubitemid 36042428)
23. Delini-Stula A, Mikkelsen H, Angst J (1995). Therapeutic efficacy of antidepressants in agitated anxious depression-a meta-analysis of moclobemide studies. Journal of Affective Disorders 35, 21-30.
24. Denninger JW, Papakostas GI, Mahal Y, Merens W, et al. (2006). Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. Psychosomatics 47, 348-352.
25. Dmitrzak-Weglarz M, Rajewska-Rager A, Gattner K, Kapelski P, et al. (2007). Association studies of 5HT2A and 5HTTLPR polymorphisms and drug response in depression patients. European Neuropsychopharmacology 17 (Suppl. 4), S238.
26. Durham LK, Webb SM, Milos PM, Clary CM, et al. (2004). The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology 174, 525-529. (Pubitemid 39119341)
27. Eller T, Vasar V, Shlik J, Maron E (2008). Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 445-450. (Pubitemid 351178962)
28. Fava M, Borus JS, Alpert JE, Nierenberg AA, et al. (1997a). Folate, vitamin B12, and homocysteine in major depressive disorder. American Journal of Psychiatry 154, 426-428. (Pubitemid 27098298)
29. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, et al. (1997b). Major depressive subtypes and treatment response. Biological Psychiatry 42, 568-576. (Pubitemid 27425475)
30. Fava M, Rush AJ, Alpert JE, Balasubramani GK, et al. (2008). Do outpatients with anxious vs. non-anxious major depressive disorder have different treatment outcomes? A STAR*D report. American Journal of Psychiatry 165, 342-351.
31. Feiger AD, Flament MF, Boyer P, Gillespie JA (2003). Sertraline vs. fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies. International Clinical Psychopharmacology 18, 203-210. (Pubitemid 36871871)
32. Flint AJ, Rifat SL (1997). Anxious depression in elderly patients: response to antidepressant treatment. American Journal of Geriatric Psychiatry 5, 107-115. (Pubitemid 27157394)
33. Friedman RA, Parides M, Baff R, Moran M, et al. (1995). Predictors of response to desipramine in dysthymia. Journal of Clinical Psychopharmacology 15, 280-283.
34. Fu CH, Williams SC, Brammer MJ, Suckling J, et al. (2007) Neural responses to happy facial expressions in major depression following antidepressant treatment. American Journal of Psychiatry 164, 599-607. (Pubitemid 46650191)
35. Fu CH, Williams SC, Cleare AJ, Brammer MJ, et al. (2004). Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Archives of General Psychiatry 61, 877-889. (Pubitemid 39181077)
36. Fu CH, Williams SC, Cleare AJ, Scott J, et al. (2008). Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biological Psychiatry 64, 505-512.
37. Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, et al. (2000). The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology 148, 404-411. (Pubitemid 30169759)
38. Gervasoni N, Aubry JM, Bondolfi G, Osiek C, et al. (2005). Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 51, 234-238. (Pubitemid 40976406)
39. Grunhaus L, Harel Y, Krugler T, Pande AC, et al. (1988). Major depressive disorder and panic disorder: effects of comorbidity on treatment outcome with antidepressant medications. Clinical Neuropharmacology 11, 454-461.
40. Grunhaus L, Rabin D, Greden JF (1986). Simultaneous panic and depressive disorder: response to antidepressant treatments. Journal of Clinical Psychiatry 47, 4-7. (Pubitemid 16182750)
41. Ham BJ, Lee BC, Paik JW, Kang RH, et al. (2007). Association between the tryptophan hydroxylase-1 gene a218C polymorphism and citalopram antidepressant response in a Korean population. Progress in Neuropsychopharmacology and Biological Psychiatry 31, 104-107.
42. Hegerl U, Juckel G (1993). Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biological Psychiatry 33, 173-187. (Pubitemid 23089966)
43. Hellweg R, Ziegenhorn A, Heuser I, Deuschle M (2008). Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 41, 66-71. (Pubitemid 351427525)
44. Hetzel G, Moeller O, Evers S, Erfurth A, et al. (2005). The astroglial protein s100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology (Berlin) 178, 161-166. (Pubitemid 40379210)
45. Hirschfeld RM, Russell JM, Delgado PL, Fawcett J, et al. (1998). Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Journal of Clinical Psychiatry 59, 669-675. (Pubitemid 29068312)
46. Hong CJ, Chen TJ, Yu YW, Tsai SJ (2006). Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in taiwan chinese major depressive disorder. Pharmacogenomics Journal 6, 27-33. (Pubitemid 43118308)
47. Horstmann S, Lucae S, Menke A, Hennings JM, et al. (2010). Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35, 727-740.
48. Hu XZ, Rush AJ, Charney D, Wilson AF, et al. (2007). Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Archives of General Psychiatry 64, 783-792. (Pubitemid 47026374)
49. Huang TL, Lee CT, Liu YL (2008). Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. Journal of Psychiatric Research 42, 521-525.
50. Hunter AM, Cook IA, Leuchter AF (2007). The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. Psychiatric Clinics of North America 30, 105-124. (Pubitemid 46394587)
51. Hunter AM, Leuchter AF, Morgan ML, Cook IA (2006). Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. American Journal of Psychiatry 163, 1426-1432. (Pubitemid 44464415)
52. Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, et al. (2008). Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biological Psychiatry 63, 1127-1134.
53. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, et al. (2005a). Cardiovascular risk factors may moderate pharmacological treatment effects in Major depressive disorder. Psychosomatic Medicine 67, 703-706. (Pubitemid 41396015)
54. Iosifescu DV, Greenwald S, Devlin P, Alpert JE, et al. (2005b). Frontal EEG at 1 Week Predicts Clinical Response to SSRIs in MDD. Presented at the 158th Annual meeting of the American Psychiatric Association, Atlanta, Georgia.
55. Iosifescu DV, Nierenberg AA, Alpert JE, Smith M, et al. (2003). The impact of medical comorbidity on acute treatment in major depressive disorder. American Journal of Psychiatry 160, 2122-2127. (Pubitemid 39619604)
56. Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, et al. (2006). Brain MRI white matter hyperintensities, cardiovascular risk factors, and treatment outcome in major depressive disorder. British Journal of Psychiatry 188, 180-185. (Pubitemid 43171076)
57. Ising M, Lucae S, Binder EB, Bettecken T, et al. (2009). A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Archives of General Psychiatry 66, 966-975.
58. Joyce PR, Mulder RT, Cloninger CR (1994). Temperament predicts clomipramine and desipramine response in major depression. Journal of Affective Disorders 30, 35-46.
59. Joyce PR, Mulder RT, Luty SE, McKenzie JM, et al. (2003). Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and g protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. International Journal of Neuropsychopharmacology 6, 339-346. (Pubitemid 38146251)
60. Juckel G, Pogarell O, Augustin H, Mulert C, et al. (2007). Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. Journal of Clinical Psychiatry 68, 1206-1212. (Pubitemid 47395622)
61. Kang RH, Wong ML, Choi MJ, Paik JW, et al. (2007). Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 31, 1317-1321.
62. Kato M, Fukuda T, Wakeno M, Fukuda K, et al. (2006). Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53, 186-195. (Pubitemid 44252779)
63. Kato M, Serretti A (2010). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 15, 473-500.
64. Kato M, Wakeno M, Okugawa G, Fukuda T, et al. (2007). No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in japanese patients with major depression. Neuropsychobiology 56, 167-171. (Pubitemid 351567532)
65. Kennedy SH, Andersen HF, Lam RW (2006). Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Journal of Psychiatry and Neuroscience 31, 122-131.
66. Kennedy SH, Anderson HF, Thase ME (2009). Escitalopram in the treatment of major depressive disorder: a meta-analysis. Current Medical Research and Opinion 25, 161-175.
67. Kessler RC, Berglund P, Demler O, Jin R, et al. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289, 3095-3105. (Pubitemid 37432885)
68. Kim DK, Lim SW, Lee S, Sohn SE, et al. (2000). Serotonin transporter gene polymorphism and antidepressant response. NeuroReport 11, 215-219. (Pubitemid 30053421)
69. Koch JM, Kell S, Hinze-Selch D, Aldenhoff JB (2002). Changes in CREB phosphorylation during recovery from major depression. Journal of Psychiatric Research 36, 369-375. (Pubitemid 35256155)
70. Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. (2006). Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials. Journal of Clinical Psychiatry 67, 761-770. (Pubitemid 43946183)
71. Kraemer HC, Wilson GT, Fairburn CG, Agras WS (2002). Mediators and moderators of treatment effects in randomized clinical trials. Archives of General Psychiatry 59, 877-883.
72. Kraft JB, Peters EJ, Slager SL, Jenkins GD, et al. (2007). Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biological Psychiatry 61, 734-742. (Pubitemid 46330243)
73. Kraft JB, Slager SL, McGrath PJ, Hamilton SP (2005). Sequence analysis of the serotonin transporter and associations with antidepressant response. Biological Psychiatry 58, 374-381. (Pubitemid 41219705)
74. Kronenberg S, Apter A, Brent D, Schirman S, et al. (2007). Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. Journal of Child and Adolescent Psychopharmacology 17, 741-750. (Pubitemid 351158594)
75. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H (2000). Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370-379. (Pubitemid 30105765)
76. Lekman M, Laje G, Charney D, Rush AJ, et al. (2008). The FKBP5-Gene in depression and treatment response-an association study in the sequenced treatment alternatives to relieve depression (STAR*D) cohort. Biological Psychiatry 63, 1103-1110.
77. Lenze EJ, Mulsant BH, Dew MA, Shear MK, et al. (2003). Good treatment outcomes in late-life depression with comorbid anxiety. Journal of Affective Disorders 77, 247-254. (Pubitemid 37377918)
78. Leuchter AF, Cook IA, Gilmer WS, Marangell LB, et al. (2009). Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Research 169, 132-138.
79. Leuchter AF, Cook IA, Lufkin RB, Dunkin J, et al. (1994). Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. NeuroImage 1, 208-219. (Pubitemid 24253436)
80. Leuchter AF, Cook IA, Witte EA, Morgan M, et al. (2002). Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry 159, 122-129. (Pubitemid 41070737)
81. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, et al. (1988). Antidepressant specificity in atypical depression. Archives of General Psychiatry 45, 129-137. (Pubitemid 18052843)
82. Linka T, Mü ller BW, Bender S, Sartory G (2004). The intensity dependence of the auditory evoked n1 component as a predictor of response to citalopram treatment in patients with major depression. Neuroscience Letters 367, 375-378. (Pubitemid 39178616)
83. Little JT, Ketter TA, Kimbrell TA, Dunn RT, et al. (2005). Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biological Psychiatry 57, 220-228. (Pubitemid 40187365)
84. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, et al. (2009). Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. Journal of Psychiatric Research 43, 247-254.
85. Mayberg HS, Brannan SK, Tekell JL, Silva JA, et al. (2000). Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biological Psychiatry 48, 830-843.
86. Mayberg HS, Silva JA, Brannan SK, Tekell JL, et al. (2002). The functional neuroanatomy of the placebo effect. American Journal of Psychiatry 159, 728-737. (Pubitemid 34465045)
87. McMahon FJ, Buervenich S, Charney D, Lipsky R, et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78, 804-814.
88. Minov C, Baghai TC, Schule C, Zwanzger P, et al. (2001). Serotonin-2A-receptor and-transporter polymorphisms: lack of association in patients with major depression. Neuroscience Letters 303, 119-122. (Pubitemid 32320019)
89. Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, et al. (2009). SLC6A4 variation and citalopram response. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics 150B, 341-351.
90. Mulert C, Juckel G, Augustin H, Hegerl U (2002). Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Clinical Neurophysiology 113, 1566-1572. (Pubitemid 35283943)
91. Mulert C, Juckel G, Brunnmeier M, Karch S, et al. (2007). Prediction of treatment response in major depression: integration of concepts. Journal of Affective Disorders 98, 215-225. (Pubitemid 46149060)
92. Nelson E, Cloninger CR (1997). Exploring the TPQ as a possible predictor of antidepressant response to nefazodone in a large multi-site study. Journal of Affective Disorders 44, 197-200. (Pubitemid 27297858)
93. Nelson EC, Cloninger CR (1995). The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression. Journal of Affective Disorders 35, 51-57.
94. Ng CH, Easteal S, Tan S, Schweitzer I, et al. (2006). Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Progress in Neuropsychopharmacology and Biological Psychiatry 30, 953-957. (Pubitemid 43795359)
95. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, et al. (2000). Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry 157, 1423-1428.
96. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, et al. (1995). Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. American Journal of Psychiatry 152, 1500-1503.
97. Paddock S, Laje G, Charney D, Rush AJ, et al. (2007). Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. American Journal of Psychiatry 164, 1181-1188. (Pubitemid 47292406)
98. Paige SR, Fitzpatrick DF, Kline JP, Balogh SE, et al. (1994). Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology 30, 197-201. (Pubitemid 24350939)
99. Papakostas GI, Petersen T, Sonawalla S, Merens W, et al. (2003a). Serum cholesterol in treatment-resistant depression. Neuropsychobiology 47, 146-151. (Pubitemid 36676978)
100. Papakostas GI, Petersen T, Iosifescu DV, Roffi P, et al. (2003b). Axis III co-morbidity in treatment-resistant depression. Psychiatry Research 118, 183-188. (Pubitemid 36694432)
101. Papakostas GI, Petersen T, Farabaugh A, Murakami J, et al. (2003c). Psychiatric comorbidity among responders and nonresponders to nortriptyline in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 64, 1357-1361. (Pubitemid 37490242)
102. Papakostas GI, Petersen T, Denninger J, Mahal Y, et al. (2003d). Somatic symptoms in treatment-resistant depression. Psychiatry Research 118, 39-45. (Pubitemid 36577559)
103. Papakostas GI, Petersen T, Iosifescu DV, Burns AM, et al. (2004a). Obesity among outpatients with major depressive disorder. International Journal of Neuropsychopharmacology 7, 1-5.
104. Papakostas GI, Petersen T, Iosifescu DV, Alpert JE, et al. (2004b). Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. Journal of Clinical Psychiatry 65, 543-546.
105. Papakostas GI, Iosifescu DV, Renshaw PF, Loo IK, et al. (2005a). Brain MRI white matter hyperintensities, cardiovascular risk factors, and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Research: Neuroimaging 140, 301-307. (Pubitemid 41660974)
106. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, et al. (2005b). The relationship between serum folate, vitamin B12 and homocysteine levels in major depressive disorder and the timing of clinical improvement to fluoxetine. International Journal of Neuropsychopharmacology 8, 523-528. (Pubitemid 41400882)
107. Papakostas GI, Fava M (2006). Does the probability of receiving placebo influence the likelihood of responding to placebo or clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Neuropsychopharmacology 31 (Suppl. 1), s158.
108. Papakostas GI, Petersen T, Pava J, Homberger BA, et al. (2007). Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. Annals of Clinical Psychiatry 19, 5-8. (Pubitemid 46439715)
109. Papakostas GI, McGrath PJ, Stewart J, Fisher LB, et al. (2008a). Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Research 161, 116-120.
110. Papakostas GI, Stahl SM, Krishen A, Seifert CA, et al. (2008b). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression). Journal of Clinical Psychiatry 69, 1287-1292.
111. Papakostas GI (2009). Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. Journal of Clinical Psychiatry 70 (Suppl. 6), 16-25.
112. Perlis RH, Moorjani P, Fagerness J, Purcell S, et al. (2008). Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 33, 2810-2819.
113. Peselow ED, Fieve RR, DiFiglia C (1992). Personality traits and response to desipramine. Journal of Affective Disorders 24, 209-216.
114. Petersen T, Papakostas GI, Posternak MA, Kant A, et al. (2005). Empirical testing of two models for staging antidepressant treatment resistance. Journal of Clinical Psychopharmacology 25, 336-341. (Pubitemid 41060253)
115. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, et al. (1991). Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Archives of General Psychiatry 48, 319-323.
116. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, et al. (1990). Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Archives of General Psychiatry 47, 935-941. (Pubitemid 20348481)
117. Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, et al. (1988). Phenelzine vs. imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. American Journal of Psychiatry 145, 306-311. (Pubitemid 18078309)
118. Rausch JL, Johnson ME, Fei YJ, Li JQ, et al. (2002). Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biological Psychiatry 51, 723-732. (Pubitemid 34450808)
119. Renshaw PF, Lafer B, Babb SM, Fava M, et al. (1997). Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry 41, 837-843. (Pubitemid 27158380)
120. Renshaw PF, Parow AM, Hirashima F, Ke Y, et al. (2001). Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. American Journal of Psychiatry 158, 2048-2055. (Pubitemid 33104113)
121. Robinson DS, Kayser A, Corcella J, Laux D, et al. (1985). Panic attacks in outpatients with depression: response to antidepressant treatment. Psychopharmacology Bulletin 21, 562-567. (Pubitemid 16240070)
122. Russell JM, Koran LM, Rush J, Hirschfeld RM, et al. (2001). Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depression and Anxiety 13, 18-27. (Pubitemid 32537090)
123. Sato K, Yoshida K, Takahashi H, Ito K, et al. (2002). Association between-1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in japanese patients with major depressive disorder. Neuropsychobiology 46, 136-140.
124. Sato T, Hirano S, Narita T, Kusunoki K, et al. (1999). Temperament and character inventory dimensions as a predictor of response to antidepressant treatment in major depression. Journal of Affective Disorders 56, 153-161. (Pubitemid 30058217)
125. Schmitt AB, Bauer M, Volz HP, Moeller HJ, et al. (2009). Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. European Archives of Psychiatry and Clinical Neuroscience 259, 329-339.
126. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE (2002). S100B is increased in mood disorders and may be reduced by antidepressive treatment. NeuroReport 13, 1675-1678.
127. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, et al. (2008). Serum markers support disease-specific glial pathology in major depression. Journal of Affective Disorders 111, 271-280.
128. Serretti A, Cusin C, Rausch JL, Bondy B, et al. (2006). Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Research 145, 61-65. (Pubitemid 44709196)
129. Serretti A, Kato M, De Ronchi D, Kinoshita T (2007). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry 12, 247-257. (Pubitemid 46328503)
130. Serretti A, Zanardi R, Rossini D, Cusin C, et al. (2001a). Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Molecular Psychiatry 6, 586-592. (Pubitemid 32772568)
131. Serretti A, Zanardi R, Cusin C, Rossini D, et al. (2001b). Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. European Neuropsychopharmacology 11, 375-380. (Pubitemid 32946888)
132. Shelton RC, Manier DH, Sanders-Bush E (2005). Signal transduction abnormalities in melancholic depression. International Journal of Neuropsychopharmacology 8, 5-16. (Pubitemid 40388809)
133. Silverstone P, Salinas E (2001). Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Journal of Clinical Psychiatry 62, 523-529. (Pubitemid 32703091)
134. Simon GE, Heiligenstein JH, Grothaus L, Katon W, et al. (1998). Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. Journal of Clinical Psychiatry 59, 49-55. (Pubitemid 28141235)
135. Sir A, D'Souza RF, Uguz S, George T, et al. (2005). Randomized trial of sertraline vs. venlafaxine XR in major depression: efficacy and discontinuation symptoms. Journal of Clinical Psychiatry 66, 1312-1320. (Pubitemid 41546512)
136. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, et al. (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular Psychiatry 3, 508-511. (Pubitemid 28515526)
137. Smits KM, Smits LJ, Schouten JS, Stelma FF, et al. (2004). Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Molecular Psychiatry 9, 433-441. (Pubitemid 38903501)
138. Sonawalla S, Papakostas GI, Petersen T, Yeung AS, et al. (2002). Elevated cholesterol levels in major depressive disorder associated with non-response to fluoxetine treatment. Psychosomatics 43, 310-316.
139. Stassen HH, Angst J, Delini-Stula A (1996). Delayed onset of action of antidepressant drugs? survey of results of zurich meta-analyses. Pharmacopsychiatry 29, 87-96. (Pubitemid 26150434)
140. Szegedi A, Rujescu D, Tadic A, Muller MJ, et al. (2005). The catechol-O methyltransferase val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics Journal 5, 49-53. (Pubitemid 40220617)
141. Taylor BP, Bruder GE, Stewart JW, McGrath PJ, et al. (2006a). Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. American Journal of Psychiatry 163, 73-78. (Pubitemid 43050106)
142. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z (2006b). Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Archives of General Psychiatry 63, 1217-1223. (Pubitemid 44708080)
143. Thase ME, Entsuah R, Cantillon M, Kornstein SG (2005). Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. Journal of Women's Health (Larchmont) 14, 609-616. (Pubitemid 41488679)
144. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, et al. (2007). Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Journal of Clinical Psychopharmacology 27, 672-676. (Pubitemid 351339455)
145. Tollefson GD, Holman SL, Sayler ME, Potvin JH (1994). Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Journal of Clinical Psychiatry 55, 50-59. (Pubitemid 24081821)
146. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 28-40. (Pubitemid 43050100)
147. Tsapakis EM, Checkley S, Kerwin RW, Aitchison KJ (2003). Association between the serotonin transporter linked polymorphic region gene (5HTTLPR) and response to tricyclic antidepressants (TCAs). European Neuropsychopharmacology 13, S250.
148. Yoshida K, Naito S, Takahashi H, Sato K, et al. (2002a). Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 26, 1279-1283. (Pubitemid 35341578)
149. Yoshida K, Ito K, Sato K, Takahashi H, et al. (2002b). Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in japanese depressed patients. Progress in Neuropsychopharmacology and Biological Psychiatry 26, 383-386. (Pubitemid 34038069)
150. Yoshimura R, Mitoma M, Sugita A, Hori H, et al. (2007). Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Progress in Neuropsychopharmacology and Biological Psychiatry 31, 1034-1037. (Pubitemid 46824019)
151. Yu YW, Tsai SJ, Chen TJ, Lin CH, et al. (2002). Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Molecular Psychiatry 7, 1115-1119. (Pubitemid 36044271)
152. Zanardi R, Benedetti F, Di Bella D, Catalano M, et al. (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of Clinical Psychopharmacology 20, 105-107. (Pubitemid 30056365)
153. Zanardi R, Serretti A, Rossini D, Franchini L, et al. (2001). Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological Psychiatry 50, 323-330. (Pubitemid 32816944)
154. Zou YF, Ye DQ, Feng XL, Su H, et al. (2010). Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. European Neuropsychopharmacology 20, 535-544.